List of Drug Master Files (DMF) of zoledronic acid anhydrous Active Pharmaceutical Ingredient listed on PharmaCompass.com

PharmaCompass

Synopsis

Related ProductsRelated Products

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Zoledronic acid disodium, Zoledronate disodium anhydrous, 165800-07-7, 5csv5k1879, 131654-46-1, Unii-5csv5k1879
Molecular Formula
C5H8N2Na2O7P2
Molecular Weight
316.05  g/mol
InChI Key
OPQQEYHAVUNQNA-UHFFFAOYSA-L
FDA UNII
5CSV5K1879

Zoledronate Disodium
Zoledronate Disodium is the disodium salt form of zoledronate, a synthetic imidazole, third generation bisphosphonate analog of pyrophosphate with antiresorptive activity. Zoledronate binds to hydroxyapatite crystals in the bone matrix and inhibits farnesyl pyrophosphate (diphosphate) synthase, thereby preventing protein prenylation within the mevalonate pathway. This leads to the loss of downstream metabolites essential for osteoclast function, leading to the induction of apoptosis and eventually, osteoclast-cell death. By preventing osteoclast-mediated bone resorption, zoledronate decreases bone turnover and stabilizes the bone matrix.
1 2D Structure

Zoledronate Disodium

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
disodium;hydroxy-[1-hydroxy-1-[hydroxy(oxido)phosphoryl]-2-imidazol-1-ylethyl]phosphinate
2.1.2 InChI
InChI=1S/C5H10N2O7P2.2Na/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7;;/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14);;/q;2*+1/p-2
2.1.3 InChI Key
OPQQEYHAVUNQNA-UHFFFAOYSA-L
2.1.4 Canonical SMILES
C1=CN(C=N1)CC(O)(P(=O)(O)[O-])P(=O)(O)[O-].[Na+].[Na+]
2.2 Other Identifiers
2.2.1 UNII
5CSV5K1879
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. Zoledronic Acid Disodium

2. Zoledronate Disodium Anhydrous

3. 165800-07-7

4. 5csv5k1879

5. 131654-46-1

6. Unii-5csv5k1879

7. Dtxsid80157167

8. Akos015969312

9. J-010228

10. Q27261841

11. Phosphonic Acid, (1-hydroxy-2-(1h-imidazol-1-yl)ethylidene)bis-, Disodium Salt

12. Phosphonic Acid, P,p'-(1-hydroxy-2-(1h-imidazol-1-yl)ethylidene)bis-, Sodium Salt (1:2)

2.4 Create Date
2006-03-21
3 Chemical and Physical Properties
Molecular Weight 316.05 g/mol
Molecular Formula C5H8N2Na2O7P2
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count8
Rotatable Bond Count4
Exact Mass315.96021316 g/mol
Monoisotopic Mass315.96021316 g/mol
Topological Polar Surface Area159 Ų
Heavy Atom Count18
Formal Charge0
Complexity322
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count3

ABOUT THIS PAGE

zoledronic acid anhydrous Manufacturers | Traders | Suppliers

zoledronic acid anhydrous Manufacturers, Traders, Suppliers 1
25

We have 1 companies offering zoledronic acid anhydrous

Get in contact with the supplier of your choice:

  1. Teva API
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty